000142116 001__ 142116
000142116 005__ 20240229105145.0
000142116 0247_ $$2doi$$a10.1016/S1470-2045(18)30364-4
000142116 0247_ $$2pmid$$apmid:30102236
000142116 0247_ $$2ISSN$$a1470-2045
000142116 0247_ $$2ISSN$$a1474-5488
000142116 0247_ $$2altmetric$$aaltmetric:45910579
000142116 037__ $$aDKFZ-2018-02346
000142116 041__ $$aeng
000142116 082__ $$a610
000142116 1001_ $$aRutkowski, Stefan$$b0
000142116 245__ $$aBiological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group.
000142116 260__ $$aLondon$$bThe Lancet Publ. Group$$c2018
000142116 3367_ $$2DRIVER$$aarticle
000142116 3367_ $$2DataCite$$aOutput Types/Journal article
000142116 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660125052_9214$$xReview Article
000142116 3367_ $$2BibTeX$$aARTICLE
000142116 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142116 3367_ $$00$$2EndNote$$aJournal Article
000142116 520__ $$aPaediatric CNS tumours are the most common cause of childhood cancer-related morbidity and mortality, and improvements in their diagnosis and treatment are needed. New genetic and epigenetic information about paediatric CNS tumours is transforming the field dramatically. For most paediatric CNS tumour entities, subgroups with distinct biological characteristics have been identified, and these characteristics are increasingly used to facilitate accurate diagnoses and therapeutic recommendations. Future treatments will be further tailored to specific molecular subtypes of disease, specific tumour predisposition syndromes, and other biological criteria. Successful biomaterial collection is a key requirement for the application of contemporary methodologies for the validation of candidate prognostic factors, the discovery of new biomarkers, the establishment of appropriate preclinical research models for targeted agents, a quicker clinical implementation of precision medicine, and for other therapeutic uses (eg, for immunotherapies). However, deficits in organisational structures and interdisciplinary cooperation are impeding the collection of high-quality biomaterial from CNS tumours in most centres. Practical, legal, and ethical guidelines for consent, storage, material transfer, biobanking, data sharing, and funding should be established by research consortia and local institutions to allow optimal collection of primary and subsequent tumour tissue, body fluids, and normal tissue. Procedures for the collection and storage of biomaterials and related data should be implemented according to the individual and organisational structures of the local institutions.
000142116 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000142116 588__ $$aDataset connected to CrossRef, PubMed,
000142116 7001_ $$aModena, Piergiorgio$$b1
000142116 7001_ $$aWilliamson, Daniel$$b2
000142116 7001_ $$aKerl, Kornelius$$b3
000142116 7001_ $$aNysom, Karsten$$b4
000142116 7001_ $$aPizer, Barry$$b5
000142116 7001_ $$aBartels, Ute$$b6
000142116 7001_ $$aPuget, Stephanie$$b7
000142116 7001_ $$aDoz, François$$b8
000142116 7001_ $$aMichalski, Antony$$b9
000142116 7001_ $$avon Hoff, Katja$$b10
000142116 7001_ $$aChevignard, Mathilde$$b11
000142116 7001_ $$aAvula, Shivaram$$b12
000142116 7001_ $$aMurray, Matthew J$$b13
000142116 7001_ $$aSchönberger, Stefan$$b14
000142116 7001_ $$aCzech, Thomas$$b15
000142116 7001_ $$aSchouten-van Meeteren, Antoinette Y N$$b16
000142116 7001_ $$aKordes, Uwe$$b17
000142116 7001_ $$aKramm, Christof M$$b18
000142116 7001_ $$avan Vuurden, Dannis G$$b19
000142116 7001_ $$aHulleman, Esther$$b20
000142116 7001_ $$aJanssens, Geert O$$b21
000142116 7001_ $$aSolanki, Guirish A$$b22
000142116 7001_ $$avan Veelen, Marie-Luise C$$b23
000142116 7001_ $$aThomale, Ulrich$$b24
000142116 7001_ $$aSchuhmann, Martin U$$b25
000142116 7001_ $$aJones, Chris$$b26
000142116 7001_ $$aGiangaspero, Felice$$b27
000142116 7001_ $$aFigarella-Branger, Dominique$$b28
000142116 7001_ $$aPietsch, Torsten$$b29
000142116 7001_ $$aClifford, Steve C$$b30
000142116 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b31$$udkfz
000142116 7001_ $$aVan Gool, Stefaan W$$b32
000142116 773__ $$0PERI:(DE-600)2035574-9$$a10.1016/S1470-2045(18)30364-4$$gVol. 19, no. 8, p. e419 - e428$$n8$$pe419 - e428$$tThe lancet <London> / Oncology Oncology$$v19$$x1470-2045$$y2018
000142116 909CO $$ooai:inrepo02.dkfz.de:142116$$pVDB
000142116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b31$$kDKFZ
000142116 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000142116 9141_ $$y2018
000142116 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142116 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142116 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142116 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET ONCOL : 2017
000142116 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000142116 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000142116 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142116 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142116 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142116 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000142116 915__ $$0StatID:(DE-HGF)9930$$2StatID$$aIF >= 30$$bLANCET ONCOL : 2017
000142116 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000142116 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000142116 980__ $$ajournal
000142116 980__ $$aVDB
000142116 980__ $$aI:(DE-He78)B062-20160331
000142116 980__ $$aI:(DE-He78)L101-20160331
000142116 980__ $$aUNRESTRICTED